June 16th 2020 – We are thrilled to announce that Eleusian Biosciences has announced an agreement to be acquired by Greenstar Biosciences – Please Click here to read the full announcement.

Eleusian Biosciences Corp., a Toronto based company, is focused on development of therapeutics for multiple pathological psychological diseases based on psilocybin plus NAcetylcysteine(NAC) compounds.

Eleusian is collaborating with a multidisciplinary team of scientists and physicians at the University of Miami to develop effective therapeutics for the treatment of mTBI (mild traumatic brain injury/concussion) with PTSD or PTSD alone based on Psilocybin (the active ingredient of psychedelic mushrooms) and N-Acetylcysteine(NAC). NAC has been shown to have efficacy in treating mTBI, particularly in reducing neuronal losses and also reducing impaired cognitive and neurological symptoms after injury to head.

As majority of patients with mTBI experience PTSD, we believe adding Psilocybin to the mixture will be effective in addressing and suppressing or erasing pathological memories involved in PTSD. This combination may also elicit positive clinical outcomes in altering destructive behavior patterns such as drug and alcohol addiction, unconstrained mental and physical activity as Obsessive Compulsive Disorders (OCD), Alzheimer’s and Parkinson’s diseases, Autism, Schizophrenia, Depression and Bipolar Disorder.